1. Home
  2. AMS vs BCDA Comparison

AMS vs BCDA Comparison

Compare AMS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

N/A

Current Price

$2.09

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

BCDA

BioCardia Inc.

N/A

Current Price

$1.30

Market Cap

14.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMS
BCDA
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AMS
BCDA
Price
$2.09
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
11.5K
67.3K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,423,000.00
N/A
Revenue This Year
$3.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.84
N/A
52 Week Low
$2.01
$1.00
52 Week High
$3.52
$3.20

Technical Indicators

Market Signals
Indicator
AMS
BCDA
Relative Strength Index (RSI) 45.92 42.35
Support Level $2.03 $1.26
Resistance Level $2.18 $1.50
Average True Range (ATR) 0.06 0.09
MACD 0.01 -0.01
Stochastic Oscillator 31.54 25.00

Price Performance

Historical Comparison
AMS
BCDA

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: